Rock Springs Capital Management LP Aeglea Bio Therapeutics, Inc. Transaction History

Rock Springs Capital Management LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.38 - $0.81 $129,911 - $276,916	341,872 Added 11.13%	3,413,906 $1.8 Million
Q2 2022 Aug 15, 2022	BUY	$0.5 - $2.66 $630,304 - $3.35 Million	1,260,609 Added 69.59%	3,072,034 $1.55 Million
Q1 2022 May 16, 2022	BUY	$1.87 - $4.77 $437,821 - $1.12 Million	234,129 Added 14.84%	1,811,425 $4.17 Million
Q1 2021 May 17, 2021	SELL	$6.76 - $8.57 $18,279 - $23,173	-2,704 Reduced 0.17%	1,577,296 $12.5 Million
Q4 2020 Feb 16, 2021	SELL	$7.02 - $9.83 $73,906 - $103,490	-10,528 Reduced 0.66%	1,580,000 $12.4 Million
Q2 2020 Aug 14, 2020	BUY	$4.01 - $11.04 $3.17 Million - $8.73 Million	790,528 Added 98.82%	1,590,528 $14.7 Million
Q1 2019 May 15, 2019	BUY	$7.6 - $9.4 $1.14 Million - $1.41 Million	150,000 Added 23.08%	800,000 $6.44 Million
Q2 2018 Aug 14, 2018	BUY	$7.87 - $10.89 $990,919 - $1.37 Million	125,911 Added 24.02%	650,000 $6.88 Million
Q3 2017 Nov 14, 2017	BUY	$2.91 - $4.93 $1.53 Million - $2.58 Million	524,089	524,089 $2.58 Million

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Rock Springs Capital Management LP with notifications on news.